GENFIT-ADR (GNFT) Stock Fundamental Analysis
NASDAQ:GNFT - Nasdaq - US3722791098 - ADR - Currency: USD
Taking everything into account, GNFT scores 4 out of 10 in our fundamental rating. GNFT was compared to 559 industry peers in the Biotechnology industry. There are concerns on the financial health of GNFT while its profitability can be described as average. GNFT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
GNFT had positive earnings in the past year.
In the past year GNFT had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 0.66%, GNFT belongs to the best of the industry, outperforming 90.34% of the companies in the same industry.
With an excellent Return On Equity value of 1.45%, GNFT belongs to the best of the industry, outperforming 91.77% of the companies in the same industry.
GNFT has a Return On Invested Capital of 3.17%. This is amongst the best in the industry. GNFT outperforms 92.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.66% | ||
| ROE | 1.45% | ||
| ROIC | 3.17% |
ROA(3y)-8.89%
ROA(5y)-10.75%
ROE(3y)-21.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GNFT has a Profit Margin of 1.41%. This is amongst the best in the industry. GNFT outperforms 91.06% of its industry peers.
GNFT's Profit Margin has declined in the last couple of years.
The Operating Margin of GNFT (4.16%) is better than 92.67% of its industry peers.
In the last couple of years the Operating Margin of GNFT has declined.
The Gross Margin of GNFT (97.11%) is better than 97.50% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.16% | ||
| PM (TTM) | 1.41% | ||
| GM | 97.11% |
OM growth 3Y-50.61%
OM growth 5YN/A
PM growth 3Y-69.97%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GNFT is destroying value.
Compared to 1 year ago, GNFT has about the same amount of shares outstanding.
Compared to 5 years ago, GNFT has more shares outstanding
Compared to 1 year ago, GNFT has a worse debt to assets ratio.
2.2 Solvency
GNFT has an Altman-Z score of -1.68. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a Altman-Z score (-1.68) which is comparable to the rest of the industry.
The Debt to FCF ratio of GNFT is 4.13, which is a neutral value as it means it would take GNFT, 4.13 years of fcf income to pay off all of its debts.
GNFT has a Debt to FCF ratio of 4.13. This is amongst the best in the industry. GNFT outperforms 93.56% of its industry peers.
GNFT has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GNFT (0.08) is worse than 64.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.13 | ||
| Altman-Z | -1.68 |
ROIC/WACC0.42
WACC7.57%
2.3 Liquidity
A Current Ratio of 1.24 indicates that GNFT should not have too much problems paying its short term obligations.
GNFT's Current ratio of 1.24 is on the low side compared to the rest of the industry. GNFT is outperformed by 84.79% of its industry peers.
A Quick Ratio of 1.24 indicates that GNFT should not have too much problems paying its short term obligations.
GNFT's Quick ratio of 1.24 is on the low side compared to the rest of the industry. GNFT is outperformed by 84.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
GNFT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.17%, which is quite impressive.
The earnings per share for GNFT have been decreasing by -70.84% on average. This is quite bad
GNFT shows a strong growth in Revenue. In the last year, the Revenue has grown by 85.82%.
Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)105.17%
EPS 3Y-70.84%
EPS 5YN/A
EPS Q2Q%-212.5%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
3.2 Future
GNFT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -45.31% yearly.
The Revenue is expected to decrease by -1.64% on average over the next years.
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.64%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 136.67, which means the current valuation is very expensive for GNFT.
91.06% of the companies in the same industry are more expensive than GNFT, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of GNFT to the average of the S&P500 Index (26.31), we can say GNFT is valued expensively.
GNFT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.67 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GNFT is valued cheaply inside the industry as 93.02% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, GNFT is valued cheaper than 96.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.74 | ||
| EV/EBITDA | 32.99 |
4.3 Compensation for Growth
GNFT has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -45.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.31%
EPS Next 3YN/A
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:GNFT (6/13/2025, 8:05:08 PM)
4.1
+0.07 (+1.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.9%
Inst Owner Change1.56%
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap204.43M
Analysts90.77
Price Target10.83 (164.15%)
Short Float %0.12%
Short Ratio3.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.75%
PT rev (3m)5.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.46%
EPS NY rev (3m)87.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)117.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.67 | ||
| Fwd PE | N/A | ||
| P/S | 2.49 | ||
| P/FCF | 11.74 | ||
| P/OCF | 11.02 | ||
| P/B | 2.56 | ||
| P/tB | 8.4 | ||
| EV/EBITDA | 32.99 |
EPS(TTM)0.03
EY0.73%
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.35
FCFY8.52%
OCF(TTM)0.37
OCFY9.07%
SpS1.65
BVpS1.6
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.66% | ||
| ROE | 1.45% | ||
| ROCE | 3.88% | ||
| ROIC | 3.17% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.16% | ||
| PM (TTM) | 1.41% | ||
| GM | 97.11% | ||
| FCFM | 21.17% |
ROA(3y)-8.89%
ROA(5y)-10.75%
ROE(3y)-21.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.61%
OM growth 5YN/A
PM growth 3Y-69.97%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.13 | ||
| Debt/EBITDA | 1.19 | ||
| Cap/Depr | 56.98% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 342.61% | ||
| Profit Quality | 1502% | ||
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | -1.68 |
F-Score7
WACC7.57%
ROIC/WACC0.42
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.17%
EPS 3Y-70.84%
EPS 5YN/A
EPS Q2Q%-212.5%
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.64%
EBIT growth 1Y111.07%
EBIT growth 3Y-53.61%
EBIT growth 5YN/A
EBIT Next Year67.69%
EBIT Next 3Y62.39%
EBIT Next 5YN/A
FCF growth 1Y126.13%
FCF growth 3Y-46.73%
FCF growth 5YN/A
OCF growth 1Y129.09%
OCF growth 3Y-45.7%
OCF growth 5YN/A